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Abstract
Aim: To describe the development of a dementia research registry, outlining the conceptual, practical and ethical
challenges, and to report initial experiences of recruiting people with dementia to it from primary and secondary
care.
Background: Women, the oldest old and ethnic minorities have been under-represented in clinical trials in
dementia. Such under-representation biases estimates of absolute effect, absolute harm and cost-effectiveness.
Research on dementia should include patient populations that more exactly reflect the population at risk. One of
the impediments to this is the lack of a suitable tool for identification of patients suitable for studies.
Construction & contents: A technology development methodology was used to develop a registry of people
with dementia and their carers. This involved phases of modelling and prototype creation, ‘bench testing’ the
prototype with experts and then ‘field testing’ the refined prototype in exemplar sites. The evaluation of the field
testing described here is based on a case study methodology.
Utility: This case study suggests that construction and population of a dementia research registry is feasible, but
initial development is complex because of the ethical and organisational difficulties. Recruitment from primary care is
particularly costly in terms of staff time and only identifies a very small number of people with dementia who were
not already known to specialist services. Recruiting people with dementia through secondary care is a resource
intensive process that takes up to six months to complete. Identifying the components of a minimum dataset was
easy but its usefulness for pre-screening potential research populations has yet to be established. Acceptance rates
are very high in the first clinic to recruit to the registry, but this may reflect the efforts of registry ‘champions’.
Discussion and Conclusions: Easier recruitment may perpetuate potential selection biases and we are not yet
able to assess the representativeness of the research-ready population recruited to the registry. The need to recruit
from wider populations, through primary and social care, remains. The success of this registry will be measured by
the proportion of people from it who are recruited to research projects, and its impact on overall accrual to
studies.
Background
UK government policy is to maintain people with
dementia syndromes in their own homes for as long as
possible [1]. However, the needs of people with demen-
tia and their carers’ are inadequately addressed at all key
points in the illness trajectory, from diagnosis through
to end of life care [2]. Further research is required to
address the obstacles to the timely recognition of
dementia syndromes in primary care [3], the support for
people with dementia and their families after diagnosis,
carer strain, what factors predict the transfer of people
with dementia syndromes to institutional care, interven-
tions to manage incontinence and challenging symptoms
[4] and the therapeutic options available to clinicians
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[5].
There are some treatments for people with Alzhei-
mer’s disease shown in trials to be effective in modifying
symptoms [6] and emerging therapies will need rigorous
evaluation in large-scale trials. The next target for che-
motherapeutic approaches in Alzheimer’s disease is the
development of disease-modifying drugs, but the design
of these trials raises many questions. Which populations
should be studied, for how long and with which princi-
pal and secondary endpoints? [7].
These questions may be difficult to answer. Difficulties
in ensuring that samples are representative have meant
that people with dementia included in clinical research
have been systematically younger than the general popu-
lation of people with dementia and that women, the
oldest old and ethnic minorities have been under-
represented. Such under-representation may not always
affect the external validity of relative effect estimates, but
measures of absolute effectiveness, absolute harm and
cost-effectiveness are associated with underlying risk
levels in different socio-demographic groups and current
under-representation will bias absolute effect estimates
[8]. Research on dementia could gain much from the
study of patient populations that more appropriately
reflect the population at risk [9]. This age differential is
significant given the potential delays in dementia diagno-
sis, progression of dementia and diminishing capacity to
give informed consent to participate in a study.
Primary care-led studies could in theory address these
methodological problems because of the heterogeneity
of the community population and given the growing
expertise in trial design and implementation, but in
practice we know from recent trials that recruitment to
studies on dementia through general practice is proble-
matic [10,11].
Promoting dementia research
These difficulties in recruitment to dementia research
prompted the National Institute of Health Research to
establish the Dementia and Neurodegenerative Research
Network (DeNDRoN). The Dementia and Neurodegen-
erative Research Network aims to improve the speed,
quality, and integration of research in dementias and
other neurodegenerative diseases, resulting in improve-
ments in prevention, diagnosis, treatment and care for
patients. DeNDRoN facilitates the development, conduct
and delivery of clinical trials and other well-designed
studies by:
1. Coordinating focused, effective investment in
National Health Service (NHS) research infrastructure
to ensure that quality research, funded by both commer-
cial and non-commercial organizations, becomes
embedded in clinical practice.
2. Building on the research strengths already present
in the UK as well as increasing general research capacity
in the field of dementia and neurodegeneration.
3. Promoting collaboration between patients, carers,
researchers, clinicians, academics, NHS Trusts, funders
and industry, to enhance sharing of resources and
expertise.
One of the impediments in accomplishing clinical
trials for the treatment of dementia is the lack of a sui-
table tool that would facilitate identification of patients
who might be recruited for studies. Registries for
patients with Motor Neurone disease and Huntington’s
disease have been long established but to date there is
no equivalent registry for such a large patient group,
those with dementia syndrome and earlier clinical, cog-
nitive manifestations of neurodegenerative disease in the
UK. The problems of recruiting the appropriate popula-
tions to trials prompted the DeNDRoN to test the con-
cept of a research registry of people with dementia and
cognitive impairment (presumed secondary to neurode-
generation) who would express an interest in participat-
ing in dementia and cognitive impairment research in
general, rather than specific studies.
Research registries
There is now considerable experience of developing
research registries, particularly in North America. Many
registries have been developed to facilitate epidemiological
studies [12] but can also offer an organized and systematic
way to maintain contact with participants from previous
research and recruit an even more diverse pool of subjects
interested in participating in future studies [13].
However, there are difficulties in developing research
registries. Registries have been used in dementia
research, to study the clinical expression of Alzheimer’s
disease [14] and to improve the flow of information in
order to increase research participation [15]. The US
Consortium to Establish a Registry for Alzheimer’sd i s -
ease (CERAD) [16] has functioned as a vehicle for a
wide range of studies and as a mechanism for develop-
ing and testing dementia-specific instruments. In 2008
the Leon Thal Symposium proposed the development of
a US National Registry and Database to meet the multi-
ple needs of the research field, including the develop-
ment of a a research programme on prevention [17].
Similarly, the European Alzheimer’s Disease Consortium
in 2010 proposed the construction of international
research registries for studies of familial Alzheimer’s dis-
ease and for therapeutic trials [18].
Whilst registries based on routinely collected data can
offer opportunities for research they pose problems of
data organisation and accuracy for researchers [19]. Pro-
spective collection of additional data requires organised
outreach from the Registry to patients, providers and staff,
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tines and addition of reminder systems to workstations
[20]. Unique challenges in recruiting and retaining partici-
pants with neurological disorders for research studies
include cognitive deficits in participants and the complex
ways in which many neurological conditions present [21].
The perceived advantages of a research registry were
that providing an opportunity for patients to show their
interest in research could allow pre-screening of
research- ready populations for different types of study,
allow more accurate assessments of study feasibility
(because the potential research population would be
known), and create the basis for cohort studies. This
paper describes a project to establish a dementia registry
and reports initial experiences of recruiting people with
dementia through primary and secondary care.
Construction and Contents
Evaluation
The evaluation of the field testing described here is
based on a case study methodology. Case study methods
are appropriate when investigators desire or are forced
by circumstances to define research topics broadly, to
cover contextual or complex multivariate conditions and
to rely on multiple sources of evidence [22]. The all-
encompassing feature of a case study is its intense focus
on a single phenomenon within its real-life context [23].
The research questions in this case study of the demen-
tia research registry are:
1) Is it feasible to develop and sustain a research regis-
ter for people with dementia?
2) What are the actions and resources required to
develop and implement a dementia research registry?
3) What are the clinical data capture requirements for
a dementia registry for the purpose of clinical trials
recruitment?
4) What are the likely recruitment rates to a dementia
research registry?
Stakeholders
DeNDRoN is funded by the UK National Institute of
Health research (NIHR) and has specific objectives that
include increasing the number of principal investigators,
research sites and numbers of patients recruited to trials.
North Thames DeNDRoN is one of the seven regional
DeNDRoN networks and is a collaboration between
three universities [Imperial College London (ICL), Queen
Mary’s University of London (QMUL) and University
College London (UCL)] and 36 NHS Trusts covering
all North London Boroughs plus areas of Essex, Hert-
fordshire and Bedfordshire (26 Acute Trusts, 10 Mental
Health Trusts). It is hosted by one NHS Trust.
The EVIDEM programme (Evidence-based Interventions
in Dementia) funded by the English National Institute of
Health Research also proposed to create a cohort of up to
2000 people with dementia and their carers, as the basis
for recruiting individuals to studies on early diagnosis, con-
tinence management, management of behavioural and psy-
chological symptoms in dementia, end-of-life care and the
application of new legislation about giving and obtaining
consent (the Mental Capacity Act 2005).
Registry design
The development of the registry was based on a stan-
dard technology development methodology, originally
derived from the construction of decision support sys-
tems [24]. This involves phases of modelling and proto-
type creation, ‘bench testing’ and refining of the
prototype with experts and then ‘field testing’ of the
refined prototype in exemplar sites.
A co-design approach [25] was taken, bringing
together researchers (in the EVIDEM programme),
research network developers (in DeNDRoN) and people
with dementia and carers, through the Patient and Pub-
lic Involvement arm of DeNDRoN.
The design team met on six occasions during 2008-9
and held monthly teleconferences to review progress.
The design team consisted of five members from the
EVIDEM programme (SI, DL, GR, JW and KK) and two
from North Thames DeNDRoN (CWR, LC) bringing
together academic, clinical and research network exper-
tise. The design team developed a prototype registry,
‘bench tested’ it with other experts in the field, and then
initiated recruitment to it, initially in one specialist pilot
site but also in selected general practices.
Expert advisors from the Centre for Health Infor-
matics at University College London were recruited to
the design team to develop the electronic database for
the registry (AT, DK). The proposals for the registry
were discussed with DeNDRoN’s patient and public
involvement working group (made up of DeNDRoN
regional workers and members of third sector organisa-
tions) and Forum (made up of people with neurodegen-
erative diseases and their carers).
Modelling, ‘bench testing’ and prototype development
The objectives agreed by the design team were:
a) To identify people with dementia and their carers
through primary and secondary health care, social
care, community care and voluntary sector organisa-
tions in the North Thames DeNDRoN region.
b) To invite patients to join a research registry.
c) To gain consent for a minimum dataset of infor-
mation about patients to be held on the research
registry.
d) To enable clinical research staff and registered
research staff to search for patients relevant to a set
Iliffe et al. BMC Medical Research Methodology 2011, 11:9
http://www.biomedcentral.com/1471-2288/11/9
Page 3 of 10of user-defined parameters, and then use that retrie-
val set as the basis for making contact (through the
patients’ clinicians).
e) To enable the registry staff to maintain a list of
studies to which the patient has been invited, is
deciding about, has consented too or is participating
in.
f) To enable appropriate matching of registry mem-
bers to research projects and further anonymised
analyses.
g) To manage all such data securely, using role
based access and maintaining an audit log.
Recruitment to the Registry would occur in the geo-
graphical area covered by the North Thames DeNDRoN.
Recruitment would occur through primary care, second-
ary care, social care (e.g. care homes), community care
(e.g. community nursing services, Admiral Nurses) and
third sector (voluntary) organisations (e.g. Alzheimer’s
Society).
The target population was defined as people of any
age with any form of dementia residing in the commu-
nity or residential care within the defined geographical
area.
The inclusion criteria chosen were: People with either
a formal specialist (imaging/neuropsychological) or
informal generalist diagnosis of dementia as well as par-
ticipants with cognitive impairment presumed secondary
to an underlying neurodegenerative disease. The case
definition includes different types of dementia syndrome
and people with dementia of differing severity (from
early to late dementia as well as the - much debated -
Mild Cognitive Impairment). We agreed to include non
ICD10-DSM-IV diagnoses, but the source and quality of
the diagnosis would be a field within the registry to
allow prospective filtering to match the quality needs of
later research projects. The exclusion criteria chosen
were: 1) People who do not speak English for whom an
interpreter could not be located and 2) those whom
their clinician believed it would be inappropriate to
approach, for specific reasons like receiving end-of-life
care, treatment for severe co-morbidity, or major beha-
viour disturbance.
Ethics committee approval
Although the primary aim of the registry was to support
research, the design team felt that it was essential to
seek ethics committee approval, in part because dimin-
ishing capacity to consent to participation in research is
a feature of dementia syndrome. In addition the Data
Protection Act requires that all patients who are identi-
fied for research projects have given their consent to be
identified in this way, and the design team believed that
an ethics committee would provide another layer of
expert opinion about how best to explain the purpose of
the registry. Finally, the rigorous and well documented
consenting process that has to be followed as per the
granting of the ethics approval provides a clear and
auditable pathway from dissemination of information
regarding the registry through the information sheets
for patients and carers, the assessment of capacity and
the storage of critical documents to defend against
future challenges which may arise.
It was also clear that recruitment of large numbers of
people with dementia and their carers would require
Research Management and Governance approvals across
multiple sites and sectors, and information management
approvals for data storage. In addition, the team had to
develop a minimum dataset and database, and devise
mechanisms for capturing data in primary and second-
ary care, and through other routes like care homes and
third sector organisations.
Constructing the minimum dataset
A minimum set was developed in three stages. In the
first stage written commentary on the secondary care
requirements of the dataset were gathered from the
North Thames DeNDRoN’s executive board, supple-
mented by individual discussions with researchers within
the local network. In the second stage face-to-face inter-
views with primary care clinicians were conducted to
discuss the potential for using data from the General
Practice reimbursement mechanism (the ‘Quality &
Outcomes Framework’) for dementia. In the third stage
members of North Thames DeNDRoN gave feedback on
the minimal dataset fields generated in the previous two
stages and the dataset was refined based on this feed-
back. Table 1 shows the contents and data fields of the
minimum dataset.
We were aware that information recorded in notes
would be variable across services and sites. This mini-
mum dataset was based on data known to be routinely
collected in secondary care clinics assessing patients
with cognitive disorders and to a lesser extent in pri-
mary care (for example, functional status data may not
be routinely recorded in primary care notes). The design
group intended that the minimum dataset would evolve
over time to be consistent amongst collaborating cen-
tres, as far as pragmatically possible.
Confidentiality
A unique identifier is assigned to all participants on the
registry, so that data are held anonymously. A file link-
ing name and unique identifier is stored separately and
securely and in accordance with the Data Protection
Act. This will be held until the participant indicates that
s/he no longer wishes their data to be included on the
registry, and six monthly reviews will allow reaffirmation
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because of the relatively rapid health status changes that
can occur in dementia syndrome. It is intended for the
registry to be comprehensive and to be able to include
all patients seen in the North Thames DeNDRoN region
in order to be representative of the patient population.
Duplication
Information on whether the patient has been/or is cur-
rently participating in research studies will be included
on the registry to avoid patients being approached for
participation in multiple projects and registry managers
will cross check key identifiers (name, date of birth,
NHS number) of potential new participants to ensure
that people and their carers are not approached
repeatedly.
Access
National and regional researchers wanting to access the
Registry will need to approach North Thames DeNDRoN
in the first instance. Prioritisation of studies within the
North Thames DeNDRoN portfolio by local researchers
is anticipated and access to the registry will reflect this
prioritisation. Governance of the Registry will be mana-
ged through DeNDRoN’s national co-ordinating centre.
Utility
Physical construction of the research registry and its use
at the first sites provided experience of the practical
problems involved in recruiting people with dementia to
a research registry. These included identification and
invitation of potential participants, judgement of capa-
city, and obtaining both official permission and actual
support from practitioners and administrators to recruit
through NHS services.
Identification of people with dementia from medical
records complied with recommendations from the Patient
Information Advisory Group (PIAG). These recommenda-
tions allow only members of the patient’s usual clinical
care team to pre-screen patient notes to identify those sui-
table for the registry. The lead clinician (or other member
of the normal clinical team responsible for the patient’s
care) would then make the first contact with the patients
identified, either in a face-to-face meeting or by letter or
telephone. This contact would be only to inform the indi-
vidual or their family about the registry; enrolment would
usually take place separately from the clinical encounter in
which the information about the registry was given. There
are exceptions to this, as some people are keen to enrol
immediately rather than wait until their next appointment.
In cases where people feel they have had sufficient time to
consider their decision, their consent can be taken on the
same day as they receive the information. Figure 1 shows
the recruitment path and steps for an individual enrolled
through a memory clinic. This process is likely to vary
slightly to reflect differing care pathways in different mem-
ory clinic services.
Judgement of Capacity
To ensure that people at all stages of the disease process
were able to join the registry required judgements about
capacity. (This proved particularly difficult in primary
Table 1 The minimum dataset
For all practices we will record Location (Primary Care Trust -PCT)
Deprivation index score.
For all clinics we will record Specialist
Clinic location
For other services we will record Location e.g. Nursing Home, Supported Accommodation, Elderly Mentally
Infirm (EMI) home
Key worker details
For all participants in the registry the following information
(extracted from practice or clinic notes) is recorded where possible:
Demographic details (name, date of birth, gender, marital status, first language,
ethnicity, address, postcode, housing status, National Health Service number)
Carer information (name, date of birth, gender, address, postcode, relationship
to person with dementia)
Practice details (name, address)
Specialist details (name, clinic details)
Cognitive status (date of most recent test and score)
Functional status (date of most recent test and score)
Behavioural/Neuropsychiatric status
Investigations (imaging and dates)
Specific dementia medication
Co-morbidity (e.g. depression, CVD, diabetes)
History of participation in trials/studies
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to research in a therapeutic trial of Gingko Biloba found
approximately 70% of individuals with mild-moderate
dementia could not give valid consent to research parti-
cipation [26]. In the case of individuals who are not able
to give informed consent, UK Medical Research Council
and European Union-Good Clinical Practice guidelines
and the principles of the UK Mental Capacity Act 2005
were followed, and assent sought from a relevant con-
sultee. This is also in accord with internationally
accepted guidelines on research involving human sub-
jects with dementia [27].
Seeking Permissions
Research Management and Governance offices at each
NHS Trust were approached for permission to approach
Trust staff and to engage them in the development of the
database. Seeking multiple permissions across provider
organisations in primary and secondary care proved to be
a lengthy process, taking up to five months. This process
was not made easier by high staff turnover rates in the
DeNDRoN research network itself and the time needed
for training, Criminal Research Bureau checks and
research passport applications for new study officers. The
steps required to engage a new clinical site as a recruit-
ment site for the registry are summed up in Table 2.
Recruitment of patients and carers to the research reg-
istry generated important lessons about sites of recruit-
ment, and about data governance.
Recruitment in secondary care
Recruitment began in the first Mental Health Trust in
early March 2009, and three other Trusts began patient
recruitment in the next 12 months, with four more initi-
ating involvement. Figure 2 shows the rates of invitation
and recruitment to the registry, the numbers engaged
through the registry in trials, over a one year period.
Acceptance of the invitation was high, at over 90%, but
the rate of recruitment has been determined by the pat-
tern of clinic attendances, with a gap of three to six
months between the invitation to join the registry and
acceptance.
Recruitment in primary care
Tests of recruitment began with five practices that were
already part of the EVIDEM programme in autumn
2009. Of 72 people with dementia identified from these
five general practices and sent information by post
about the research registry, three responded that they
were not interested in research or finding out more and
1 8r e s p o n d e dt h a tt h e yw e r ei n t e r e s t e da n dw a n tt o
know more. Fifty one did not respond to the invitation.
Amongst those expressing interest in the research reg-
istry ten people were attending specialist clinics already
working with the research registry, and their details
were passed onto the appropriate clinic. Three lived in
Care Homes, and an assistant psychologist obtained the
carer’s agreement to gather data for one of them. She
did not meet the patient to assess capacity, but both the
 
Clinician / delegate approaches patient in 
person Makes judgement of patient’s 
capacity to consent 
Interested: 
Gives information sheets and consent 
forms 
Not interested: 
Declined 
(Option to phone local number & have 
questions answered) 
Consent forms can be signed on the day if  
patient/carer  have had sufficient time to 
consider the implications & have questions 
answered. Consented 
Patient Consent form and Carer Consent 
form can be returned in the post    
Consented 
At next appointment – clinician / delegate 
asks if patient and carer want to consent. 
Answer any questions they have. 
Want to sign: Consented  Do not want to sign: Declined 
Figure 1 Recruiting patients and carers to the Dementia Registry.
Iliffe et al. BMC Medical Research Methodology 2011, 11:9
http://www.biomedcentral.com/1471-2288/11/9
Page 6 of 10GP and the Care Home manager judged that the resi-
dent lacked capacity for this decision. The data gathered
did not contain information about medication or MMSE
score, and the psychologist extracting the data was
unsure which of two documented diagnoses was correct.
For the other two individuals the assistant psychologist
had to meet with distant relatives as care home staff did
not feel able to give an opinion about participation in
research.
The assistant psychologist also arranged a meeting, at
a hospital site, with two of the three who were not seen
in any other service. The remaining person not seen in
any other service lived in an area distant from any ser-
vice that the psychologist could invite them to, and the
assistant psychologist was uncomfortable with home vis-
its, so this individual’s expression of interest was not
pursued.
Testing the process of recruitment in general practice
was undertaken by the EVIDEM team and in specialist
clinics by NT DeNDRoN, but responsibility for subse-
quent six monthly follow-up and review did not clearly
belong to either party and had to be decided through
discussion. The situation was complicated by the organi-
sation of research infrastructure in England, where three
research networks may be involved in dementia
research: DeNDRoN, the Primary Care Research net-
work (PCRN), which recruits general practitioners for
research projects, and the Comprehensive Local
Table 2 Getting a new specialist site to recruitment stage requires
A principal investigator to act as champion for that site
Local Research Management & Governance approval
Resources for a local co-ordinator, who initially carries out and then coordinates data entry, acts as contact person for data queries and liaises with
site staff about recruiting patients. To date the financial resources have come from different streams of research network funding. New staff may
need to be recruited, or honorary contracts established for those already in other posts.
Agreement from local IT departments who need to give new staff access to electronic databases, and to set up shared drives where none existed
previously. The local information governance manager needs to be satisfied about data security.
Service manager agreement to provide office space, promote the use of the registry to front line clinical staff, allow computer use and staff
involvement in seeking consent, as well as facilitating best working practices for each site.
Site team involvement in supporting the lead clinician in identification of patients to inform about the study
Recruitment to the dementia registry
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Figure 2 Recruitment to the registry 2009-2010.
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ment of practitioners in research work. These three
types of network do not have the same boundaries, so
trilateral negotiations were necessary in different geogra-
phical locations to allow the EVIDEM team to test
recruitment to the registry through general practice.
Data governance
A decision had to be made about who would ultimately
hold and be responsible for the data collected in this
way. The information sheets state that documents and
registry data would be stored by the registry team at
North Thames DeNDRoN. However, North Thames
DeNDRoN is not a legal entity. As such, documents and
registry data are stored by West London Mental Health
Trust in accordance with agreements from North
Thames DeNDRoN for the prototype, and are only
accessible by the clinical and research staff within the
involved NHS Trust’s boundaries.
Discussion
Feasibility
The North Thames DeNDRoN dementia registry is a
pioneering project in the United Kingdom. This case
study suggests that construction and population of a
dementia research registry is feasible, but that the initial
development is complex because of the ethical difficul-
ties in dementia research and the organisational difficul-
ties in embedding research projects in NHS clinical
services. Recruitment from primary care has proved pro-
blematic; enrolment of patients is particularly costly in
terms of staff time especially given the very small num-
ber of people with dementia identified who were not
already known to specialist services. The logistics of
recruitment in memory clinics was relatively easy to
establish because of the concentration of patients and
staff as well as the rigorous application of care pathways
into which the recruitment process can be embedded.
Even then, given the timescale of clinic attendance and
the restrictions on obtaining informed consent, the
recruitment process may take up to six months.
Resource issues
Recruiting people with dementia to the registry through
secondary care is still a resource intensive process.
Potential registry members need to be identified as sui-
table, informed about the registry, met again to obtain
consent and to capture information for the minimum
dataset, and reviewed every six months to confirm their
continued interest and update their dataset. The preli-
minary steps in gaining the necessary permissions and
resources to establish the registry at a new site require
effort (a manager able to devote sufficient time) and up
to five months of preparatory work (decreasing as time
and experience informs the process). However, early
investment of effort will ensure that not only will local
clinical teams be invested in the process but it also
ensures that data collected thereafter will be both accu-
rate and complete. The costs of developing and running
the registry are core service support costs and will
therefore be borne by the NIHR Clinical Research Net-
work. DeNDRoN proposes to fund the registry through
existing funds, given the current financial climate, but
it is also part of DeNDRoN’s five year strategy
(2010-2015) to develop a broad coalition to secure
appropriate funding arrangements for the registry in the
longer term.
Clinical Data requirements
Identifying the components of a minimum dataset was
an early achievement of the design team, which is being
tested as researchers begin to use the register to recruit
to studies. The effectiveness of the registry’s minimum
dataset (as currently designed) as a device for pre-
screening potential research populations has yet to be
established.
Recruitment
Acceptance rates are very high in the first clinic to
recruit to the registry, but this may reflect the efforts of
registry ‘champions’. We are monitoring recruitment in
more recently recruited clinics where there may be less
ownership and hence less commitment to registry devel-
opment; this will give us an estimate of the likely growth
of a dementia research registry within usual NHS clini-
cal practice. Easier recruitment may perpetuate potential
selection biases and we are not yet able to assess the
representativeness of the research-ready population
recruited to the registry; this is an issue that needs to be
revisited in the next stages of registry development. The
design team will need to reconsider ways of increasing
recruitment through primary care, and through care
homes and social services, to offset biases inherent in
clinic recruitment.
Conclusions
We believe that the registry will assist in connecting
people with dementia and their carers with high quality
research studies that will help us answer important
questions regarding the pathology, clinical pathways,
aetiology, experiences of and best treatments for neuro-
degenerative disease. Only through careful scrutiny of
our processes in developing the registry and articulating
the problems faced will we deliver within the DeNDRoN
research network a state-of-the-art recruitment tool.
The primary obstacle to the development of the regis-
try has been the complexity of permission processes
within the NHS, an experience noted by others [28].
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attitudes and clinical priorities may become more sali-
ent, as found in other registries [18]. A number of
important characteristics of the registry are awaiting
evaluation, including the utility to researchers of the
minimum dataset, the representativeness of the popula-
tion recruited to the registry and the cost per person
recruited to studies through the registry. Recruitment
from sources other than specialist clinics needs further
investigation, to achieve a more representative popula-
tion of research-ready people with dementia.
The success of this prototype will be measured by the
proportion of people from the registry who participate in
research studies and the impact that the registry has on
overall accrual to portfolio studies. If these outcomes are
positive, and if recruitment to the registry becomes part of
the activity of other research sites within North Thames,
the methodology of the registry will be made available for
all local research networks within DeNDRoN.
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